|
(Health-NewsWire.Net, October 31, 2021 )
Market Overview
The comprehensive metabolic panel, also known as the chemical screen, consists of 14 blood tests used as an initial broad medical screening tool.
View full report: https://bit.ly/3GxBqQq
Market Dynamics
The factors driving the market are the rising awareness among people about diagnosis of disease and advancements in point of care diagnostics in people.
Rising awareness among people about diagnosis of disease is expected to drive the market growth
Clinical laboratory tests have an incalculable impact on health care providers' diagnostic and treatment decisions. At a time when evidence-based laboratory medicine (EBLM) is becoming more popular among health care professionals, the information provided by clinical lab tests aids in the accurate and timely diagnosis, treatment, and monitoring of patients.
The comprehensive metabolic panel (CMP) is a broad screening tool used to assess the health of organs and screen for conditions like diabetes, liver disease, and kidney disease.
Disease and symptom awareness is critical for screening and early detection. When the general public is aware of a disease and its symptoms, they are more likely to take precautions to avoid contracting it or to visit a healthcare provider for a check-up.
The majority of people receive a CMP as part of their yearly check-up. The doctor may also want one to check for problems, monitor any chronic conditions have, or ensure that certain medications aren't harming the liver or kidneys. A comprehensive metabolic panel (CMP-14) consists of 14 different blood tests that provide information on one's body's levels of glucose, calcium, proteins, electrolytes, and lipid panel, as well as liver and kidney function.
Hence, rising awareness among people about disease diagnosis is expected to drive the market. Health care providers' diagnostic and treatment decisions. At a time when evidence-based laboratory medicine (EBLM) is becoming more popular among health care professionals, the information provided by clinical lab tests aids in the accurate and timely diagnosis, treatment, and monitoring of patients. The comprehensive metabolic panel (CMP) is a broad screening tool used to assess the health of organs and screen for conditions like diabetes, liver disease, and kidney disease.
Disease and symptom awareness is critical for screening and early detection. When the general public is aware of a disease and its symptoms, they are more likely to take precautions to avoid contracting it or to visit a healthcare provider for a check-up. The majority of people receive a CMP as part of their yearly check-up.
The doctor may also want one to check for problems, monitor any chronic conditions have, or ensure that certain medications aren't harming the liver or kidneys. A comprehensive metabolic panel (CMP-14) consists of 14 different blood tests that provide information on one's body's levels of glucose, calcium, proteins, electrolytes, and lipid panel, as well as liver and kidney function. Hence, rising awareness among people about disease diagnosis is expected to drive the market.
Download free sample: https://bit.ly/3BqdlYb
Market Segmentation
Global Comprehensive Metabolic Panel Market- By Disease
Kidney Diseases
Diabetes
Liver Diseases
Other
Global Comprehensive Metabolic Panel Market- By End User
Point-of-care Centers
Laboratories
Others
Global Comprehensive Metabolic Panel Market- By Region
North America
Europe
South America
Asia Pacific
Middle East and Africa
Competitive Landscape
The global comprehensive metabolic panel market is highly competitive with rising disease incidence, advancement in diagnostic procedures, product launches and mergers. Some of the major key players in the global comprehensive metabolic panel market are Weldonbiotech, McKesson Medical-Surgical, Abaxis, Beckman Coulter,UNIPATH, Nova Biomedical, Werfen among others
Nova Biomedical:
Overview: Nova Biomedical designs, manufacture and sells high-tech blood testing analyzers. We employ over 1,400 people and have sales and service subsidiaries in eight countries as well as distributors in an additional 91 countries. Nova has manufacturing facilities in Waltham, Billerica, and Taipei, Massachusetts, as well as Taipei, Taiwan. Nova is one of the world's top 25 in vitro diagnostic companies and the largest privately held in vitro diagnostic company in the United States.
Trending Topic's, Severe Combined Immunodeficiency Diagnosis Market, Urinalysis Testing Products Market, Non-Invasive Prenatal Testing Market, Chlamydia Infection Diagnostics Market, Laboratory Proficiency Testing Market
DataM Intelligence
Sai Kiran
+1 877 441 4866
pr@datamintelligence.com
Source: EmailWire.Com 
|
